Antibody responses after intravaginal immunisation with trimeric HIV-1CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation-Reference-Cited by-同舟云学术

Antibody responses after intravaginal immunisation with trimeric HIV-1CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation

Published:2011-02 Issue:7 Volume:29 Page:1421-1430
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Cranage Martin P.,Fraser Carol A.,Cope Alethea,McKay Paul F.,Seaman Michael S.,Cole Tom,Mahmoud A. Nasir,Hall Joanna,Giles Elaine,Voss Gerald,Page Mark,Almond Neil,Shattock Robin J.

Funder

Bill & Melinda Gates Foundation

Wellcome Trust

AIDS Vaccine Discovery/Comprehensive Antibody–Vaccine Immune Monitoring Consortium

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference48 articles.

1. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites;Kwong;Nature,2002

2. HIV vaccine design and the neutralizing antibody problem;Burton;Nat Immunol,2004

3. A role for carbohydrates in immune evasion in AIDS;Reitter;Nat Med,1998